Health

OpenAI prices healthcare back-office work at 8.5 cents a task, undercutting Ambience Healthcare

OpenAI's new healthcare agents run prior-authorization work at 8.5 cents a task, and Menlo Ventures says the scribe market's new dollars are going to Microsoft and Epic. Ambience's $37,500-per-doctor receipt is now the only thing it sells that the model layer does not.

Vincent JiangVincent Jiangtwo-minute read
Share
Nikhil Buduma, chief executive of Ambience Healthcare, smiling in a gray blazer outdoors
Nikhil Buduma, chief executive of Ambience Healthcare, whose KLAS-validated $37,500 of extra annual productivity per emergency physician is the receipt OpenAI's 8.5-cent task now sits beneath.

A machine opened an insurer's website, read a patient's chart, filled in a prior-authorization request, and then did the thing that matters: it stopped, flagged the ambiguous record, and waited for a clinician's approval, logging every click on the way. That agent belongs to Ambience Healthcare~$1.25B — Ambience Healthcare, private, latest valuation ~$1.25B, the San Francisco company that drafts clinical notes for health systems, and OpenAI$1.18T — OpenAI, private, latest valuation $1.18T put it on stage on November 16 as one of four deployment partners for its new healthcare computer-use agents, alongside CVS Health−3.40% — CVS Health, down 3.40 percent today, Cigna−1.15% — Cigna, down 1.15 percent today Healthcare and Abridge$6.69B — Abridge, private, latest valuation $6.69B 1.

The back office just got a price tag

The number OpenAI attached is the story. On HealthAdminBench, a Stanford-built benchmark of prior authorizations, claim appeals and equipment orders, GPT-6 Luna scored 91.8% of available rubric points at 8.5 cents per task, 98% less than its larger sibling GPT-6 Astra, which scored 94.3% 14. Administrative work that vendors sell as software suites is now priced like electricity.

Luna trails Astra by 2.5 points on admin work and costs 98% less

  • GPT-6 Astra
  • GPT-6 Luna
0%50%100%Clinical safety (325 tasks)Physician helpfulness (646 reviews)HealthAdminBench (prior auth)
Data
GPT-6 AstraGPT-6 Luna
Clinical safety (325 tasks)99%—
Physician helpfulness (646 reviews)93%—
HealthAdminBench (prior auth)94.3%91.8%
OpenAI's reported scores for GPT-6 Astra and GPT-6 Luna, in percent: clinical safety across 325 tasks, physician helpfulness across 646 reviews, and HealthAdminBench rubric points on prior authorizations, claim appeals and equipment orders. Luna's 8.5 cents per task is 98% below Astra's. Sources: OpenAI [1], Unite.AI [4].1,4

That lands on Ambience at an awkward moment. Its validated edge is a receipt, not a demo: a KLAS study published November 3 found about $37,500 of extra annual productivity per emergency physician at Memorial Hermann 8. But the prior-auth workflow it demoed this week is administrative automation, and OpenAI's same launch put Ambience's rivals Assort Health and Infinitus Relay inside ChatGPT for Healthcare as plugins, next to Availity, Stedi, TriZetto and UpToDate 23.

The money is moving, and not to the scribes

Menlo Ventures, reporting the same day, put healthcare AI spending at $3.7 billion in 2026, 2.5 times the prior year, with ambient scribing at $950 million 6. Established vendors took 68% of new documentation spend, Microsoft−1.38% — Microsoft, down 1.38 percent today Dragon Copilot and Epic's Art lifting their share from 33% to 46% 6. The listed winners are Microsoft, Epic and the model layer itself.

Microsoft and Epic now take 46% of new documentation spend, up from 33%

  • Microsoft + Epic46%46%
  • Other established vendors22%22%
  • All other vendors32%32%
Data
SliceValueShare
Microsoft + Epic46%46%
Other established vendors22%22%
All other vendors32%32%
Share of new documentation spend won in 2026, per Menlo Ventures' survey as reported by Becker's: Microsoft's Dragon Copilot and Epic's Art at 46%, other established vendors at 22% (the 68% established-vendor total less Microsoft and Epic), all other vendors at 32%. Microsoft and Epic stood at 33% a year earlier. Source: Becker's Hospital Review [6].6

The honest caveat: these are benchmark scores, not clinical outcomes, and HealthAdminBench counts full success only when every subtask passes; OpenAI's own health AI chief has acknowledged agents can still overreach 5. Menlo's survey also carries a conflict, as the firm invests in companies it ranks 6.

What to watch is whether Ambience prices the audited workflow and its outcome contracts rather than the task, because the task now costs 8.5 cents 18. Whoever owns the receipt owns the margin 18. Deep dive in the sources below for the full picture.

For earlier coverage of OpenAI's healthcare push, see our October 29 piece on Anima.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading MSFT

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

    The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Health

    ACP licenses its guidelines to OpenEvidence for an undisclosed price

    The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

    Health

    FDA orders NAION vision-loss warning on every GLP-1 label; Novo Nordisk up 2.65%, Eli Lilly up 4.28%

    The FDA's class-wide vision-loss warning on the world's biggest drug franchise rests on ten probable cases against five among placebo patients; Novo Nordisk and Eli Lilly rose on the news, and hundreds of blindness suits now hold a federal exhibit.

    Subscribe to TheInference for free